(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as ...

The drugmakers Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price—a move that follows the Trump administration’s ...

Bristol Myers Squibb and Pfizer are launching a direct-to-patient program with 40% discount on Eliquis, reducing the monthly cost from $606 to $346 for eligible patients.

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients. The list price for Eliquis (apixaban) is ...

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass ...

Starting September 8, eligible patients can buy Eliquis through the Eliquis 360 Support program for $346 per month, a 43% discount from its current list price of about $606.

BMS and Pfizer have established a direct-to-patient online program, Eliquis 360 Support, which offers the blood thinner at a discount price.

A 30-day supply of Eliquis currently has a list price of $606, but would cost $346 per month under the new program, according to a report from the Wall Street Journal. Since its approval in 2012 ...

Eliquis will be sold directly to U.S. patients for $346/month—over 40% less than its $606 list price. Starting Sept. 8, eligible patients can order Eliquis online with nationwide shipping via ...

The drugmakers Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price—a move that follows the Trump administration’s ...